PharmaCyte Biotech Aims for Consolidated Therapy to Address Unmet Medical Need in Upcoming Cancer Clinical Trial
October 15 2015 - 9:25AM
Marketwired
PharmaCyte Biotech Aims for Consolidated Therapy to Address
Unmet Medical Need in Upcoming Cancer Clinical Trial
NEW YORK, NY - PharmaCyte Biotechs (OTCQB: PMCB) advanced
pancreatic cancer treatment of Cell-in-a-Box capsules +
low-doses of ifosfamide has outperformed Eli Lillys anti-cancer
chemotherapy drug Gemzar or gemcitabine in early phase
clinical trials when compared to historical data for gemcitabine in
3 key areas, median survival time, one-year survivors and harmful
side effects. PharmaCytes treatment also showed better data in
those same 3 areas in early phase trials than Celgenes
Abraxane plus gemcitabine, the current gold standard, offers
patients.
It now appears that the small Silver Spring, Maryland, biotech
firm plans to live by the motto, if you can beat them, join
them. This week PharmaCyte announced that it has redesigned its
upcoming clinical trial in pancreatic cancer to address a critical
unmet medical need.
According to the company, the trial is designed to provide an
effective treatment for the large percentage of patients who no
longer respond to the gold standard for the treatment of advanced
pancreatic cancer. PharmaCyte said that there are few options for
further treatment available to those patients, and even those
treatments are only marginally effective.
Interestingly, it was a team of world renowned oncologists, who
are advising/consulting with the company on what is the best way to
utilize PharmaCytes technology, that believe that the biotechs
treatment (Cell-in-a-Box capsules + low-doses of ifosfamide)
could play an important role in what has been termed a
consolidation therapy in the further treatment of patients. It is
those patients whose tumors neither progress nor show signs of
tumor reduction that there is no effective treatment alternative
beyond the current gold standard. It is believed by these
oncologists and by the company that PharmaCytes treatment for
pancreatic cancer may fill this critical unmet medical need for
these patients.
It is this term, consolidation therapy, that caught our eye. It
now appears that PharmaCyte has been advised that its treatment
could work in concert with Abraxane plus gemcitabine in some way as
part of a treatment regimen that offers patients a better option
than what is available to patients today beyond the current
standard of care (Abraxane plus gemcitabine). If the company is
able to produce significant data during its clinical trial, is
there a chance that PharmaCyte could become part of what
oncologists worldwide prescribe to their advanced pancreatic cancer
patients? If so, this new trial design is a homerun for
PharmaCyte.
The company also mentioned that it would be conducting its
planned clinical trial for the pain associated with advanced
pancreatic cancer tumors, as part of the companys upcoming clinical
trial. This is another brilliant move by the executives at
PharmaCyte. By using the patients enrolled in its upcoming clinical
trial to study the pain associated with pancreatic cancer,
PharmaCyte is dramatically reducing the time and the money it will
have to spend to study this important Quality of Life treatment,
and at the same time, potentially creating even stronger data to
present to the FDA from the clinical trial about to take place.
About Stock Market Media Group
Stock Market Media Group is a Content Development IR firm
offering a platform for corporate stories to unfold in the media
with research reports, corporate videos, CEO interviews and feature
news articles. This article was written based upon publicly
available information. PharmaCyte Biotech has not endorsed this
article, and Stock Market Media Group was not compensated for its
production.
Stock Market Media Group may from time to time include our own
opinions about the companies, their business, markets and
opportunities in our articles. Any opinions we may offer about any
of the companies we write about are solely our own, and are made in
reliance upon our rights under the First Amendment to the U.S.
Constitution, and are provided solely for the general opinionated
discussion of our readers. Our opinions should not be considered to
be complete, precise, accurate, or current investment advice, or
construed or interpreted as research. Any investment decisions you
may make concerning any of the securities we write about are solely
your responsibility based on your own due diligence. Our
publications are provided only as an informational aid, and as a
starting point for doing additional independent research. We
encourage you to invest carefully and read the investor information
available at the web site of the U.S. Securities and Exchange
Commission at: www.sec.gov, where you can also find all of
PMCBs filings and disclosures. We also recommend, as a general
rule, that before investing in any securities you consult with a
professional financial planner or advisor, and you should conduct a
complete and independent investigation before investing in any
security after prudent consideration of all pertinent risks.
We are not a registered broker, dealer, analyst, or adviser. We
hold no investment licenses and may not sell, offer to sell or
offer to buy any security. Our publications about any of the
companies we write about are not a recommendation to buy or sell a
security.
For more information: www.stockmarketmediagroup.com.
Contact:
Stock Market Media Group
info@stockmarketmediagroup.com